Clinical Applications of DNA Vaccines: Current Progress
Top Cited Papers
Open Access
- 15 July 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (3) , 296-302
- https://doi.org/10.1093/cid/cir334
Abstract
It was discovered almost 20 years ago that plasmid DNA, when injected into the skin or muscle of mice, could induce immune responses to encoded antigens. Since that time, there has since been much progress in understanding the basic biology behind this deceptively simple vaccine platform and much technological advancement to enhance immune potency. Among these advancements are improved formulations and improved physical methods of delivery, which increase the uptake of vaccine plasmids by cells; optimization of vaccine vectors and encoded antigens; and the development of novel formulations and adjuvants to augment and direct the host immune response. The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas. This review focuses on these advances and discusses both preventive and immunotherapeutic clinical applications.Keywords
This publication has 50 references indexed in Scilit:
- IL-28B/IFN-λ3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in MacaquesMolecular Therapy, 2010
- Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus MacaquesMolecular Therapy, 2010
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidityVaccine, 2010
- Therapeutic HPV DNA vaccinesImmunologic Research, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialPublished by Elsevier ,2008
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineVirology, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene InsertsToxicological Sciences, 2006